Thephamongkhol Kullathorn, Setakornnukul Jiraporn, Rojwatkarnjana Sunanta, Chansilpa Yaowalak
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok - Thailand.
Int J Biol Markers. 2014 Dec 9;29(4):e387-94. doi: 10.5301/jbm.5000106.
INTRODUCTION/AIM: To evaluate the prognostic properties of retropharyngeal lymph node (RP), posterior cervical lymph node (PCN), and supraclavicular lymph node (SPC), in stage IVA/IVB nasopharyngeal carcinoma (NPC) patients in setting of induction chemotherapy.
We performed a retrospective study including 43 patients with stage IVA/IVB NPC (7th AJCC) treated with induction chemotherapy followed by concurrent chemo-radiotherapy. We analyzed prognosis with the multivariate Cox regression model and p-value from the Wald's test, using the backward elimination method (by likelihood ratio test and percent change of coefficient factors).
Overall, 24 patients (55.8%) were in stage IVA and 19 (44.2%) in stage IVB. After a median follow-up time of 30 months, the 2-year overall survival (OS) was 79.1%, while the 2-year progression free survival (PFS) and distant metastasis free survival (DMFS) were 59.8% and 69.1%, respectively. In multivariate analysis for predicting DMFS, SPC involvement was not statistically significant (HR 3.39; 95% CI 0.76-15.07; p=0.1), whereas RP involvement was statistically significant (HR 5.81; 95% CI 1.08-31.16; p=0.04). Moreover, and more importantly, PCN involvement was the only nodal factor to predict all of DMFS, PFS, and OS (respectively HR 5.57, 95% CI 1.12-27.71, p=0.036; HR 16.05, 95% CI 1.93-133.65, p=0.01; and HR 28.02, 95% CI 2.74-286.22, p=0.005).
PCN involvement is the only independent prognostic factor of stage IVA/IVB NPC patients treated by induction chemotherapy that predicts DMFS and turns this effect to PFS and OS. PCN involvement is a highly accurate predictor for failure of conventional chemo-radiotherapy. Therefore, patients with PCN involvement should be defined at high-risk, as to be investigated for a new staging system.
引言/目的:评估诱导化疗背景下,咽后淋巴结(RP)、颈后淋巴结(PCN)和锁骨上淋巴结(SPC)对IVA/IVB期鼻咽癌(NPC)患者的预后影响。
我们进行了一项回顾性研究,纳入43例接受诱导化疗后行同步放化疗的IVA/IVB期NPC患者(第7版美国癌症联合委员会分期系统)。我们使用多因素Cox回归模型和Wald检验的p值进行预后分析,采用向后逐步回归法(似然比检验和系数因子百分比变化)。
总体而言,24例患者(55.8%)为IVA期,19例(44.2%)为IVB期。中位随访时间30个月后,2年总生存率(OS)为79.1%,2年无进展生存率(PFS)和无远处转移生存率(DMFS)分别为59.8%和69.1%。在预测DMFS的多因素分析中,SPC受累无统计学意义(风险比[HR] 3.39;95%置信区间[CI] 0.76 - 15.07;p = 0.1),而RP受累有统计学意义(HR 5.81;95% CI 1.08 - 31.16;p = 0.04)。此外,更重要的是,PCN受累是预测DMFS、PFS和OS的唯一淋巴结因素(分别为HR 5.57,95% CI 1.12 - 27.71,p = 0.036;HR 16.05,95% CI 1.93 - 133.65,p = 0.01;HR 28.02,95% CI 2.74 - 286.22,p = 0.005)。
PCN受累是接受诱导化疗的IVA/IVB期NPC患者中预测DMFS的唯一独立预后因素,并将此影响扩展至PFS和OS。PCN受累是传统放化疗失败的高度准确预测指标。因此,PCN受累的患者应被定义为高危患者,以便研究新的分期系统。